Skip to main content

Lixisenatide Reduces Motor Disability Progression in Parkinson Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on April 4, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, April 4, 2024 -- For patients with Parkinson disease, lixisenatide yields less progression of motor disability than placebo, according to a study published in the April 4 issue of the New England Journal of Medicine.

Wassilios G. Meissner, M.D., Ph.D., from the French Clinical Research Network for Parkinson's Disease and Movement Disorder in Toulouse, and colleagues conducted a phase 2 randomized trial involving patients with Parkinson disease. Participants who were diagnosed less than three years earlier, receiving a stable dose of medications to treat symptoms, and did not have motor complications were randomly assigned to daily subcutaneous lixisenatide or placebo for 12 months in a 1:1 ratio (78 participants in each group) followed by a two-month washout period.

The researchers found that scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III had changed by −0.04 points and 3.04 points in the lixisenatide and placebo groups, indicating improvement and worsening disability, respectively. After a two-month washout period, at 14 months, the mean MDS-UPDRS motor scores were 17.7 and 20.6 with lixisenatide and placebo, respectively, in the off-medication state. Nausea and vomiting occurred in 46 and 13 percent, respectively, of participants receiving lixisenatide.

"The glucagon-like peptide-1 receptor agonist lixisenatide had a three-point beneficial effect, as compared with placebo, in the change over a 12-month period from a baseline value of approximately 15 points on a 132-point scale measuring motor disability," the authors write.

Sanofi provided the medication and placebo for the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

American Academy of Neurology, April 13-18

The annual meeting of the American Academy of Neurology was held this year from April 13 to 18 in Denver, drawing participants from around the world, including clinicians...

Subcutaneous Infusion of Levodopa-Carbidopa Beneficial for Parkinson Disease

THURSDAY, April 11, 2024 -- Subcutaneous infusion of ND0612 (a levodopa-carbidopa solution) increases on time without troublesome dyskinesia among patients with Parkinson disease...

Cutaneous Phosphorylated α-Synuclein Frequently ID'd in Synucleinopathies

MONDAY, March 25, 2024 -- A high proportion of individuals with synucleinopathies has positivity for cutaneous phosphorylated α-synuclein, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.